NCT00651404View on ClinicalTrials.gov

Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

PHASE3CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

HypercholesterolemiaAtherosclerosis

Interventions

DRUG

Ezetimibe

oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)

DRUG

Placebo

oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00651404 - Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406) | Biotech Hunter | Biotech Hunter